Veradermics, Inc (MANE) Current Ratio
- Current ratio · latest quarter: Value 70.53×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 70.53× | Current assets / current liabilities. $824.75M ÷ $11.69M ≈ 70.53× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 824.75M USD | Assets, Current |
| Current obligations | 11.69M USD | Liabilities, Current |
| Cash and equivalents | 319.33M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 500.56M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 5.92M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $824.75M | $11.69M | $319.33M | $500.56M | (m) | (m) | $5.92M | (m) | 70.53× |
| 2026-03-31 | $397.07M | $6.72M | $168.41M | $222.38M | (m) | (m) | $1.07M | (m) | 59.12× |
| 2025-12-31 | $152.49M | $9.15M | $21.77M | $120.10M | (m) | (m) | $2.13M | (m) | 16.66× |
| 2024-12-31 | $55.53M | $4.72M | $53.08M | $0.00 | (m) | (m) | $2.25M | (m) | 11.77× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |